annual Report 2009 - STRATEC Biomedical AG

Report of the board of Management
Report of the supervisory board
THE share
Corporate Governance
Group Management report
Consolidated financial statements
Service
The short-term portion of total compensation amounted to u 909 thousand (previous year: u 694 thousand).
The figure stated for share-based payments involves the period-specific arithmetical value of the stock options issued to
members of the Board of Management recognized pursuant to IFRS 2 as personnel expenses in the financial year under
report. A total of 110,000 stock options with a subscription price of u 13.99 and an arithmetical total value of u 201 thousand
were issued to the Board of Management in the 2009 financial year (previous year: 85,000 stock options with a
subscription price of u 11.98 and an arithmetical total value of u 186 thousand).
Pension provisions for members of the Board of Management have been recognized as liabilities of u 106 thousand in
the consolidated financial statements (previous year: u 0 thousand).
Hermann Leistner is Managing Director of STRATEC NewGen GmbH, Birkenfeld. Marcus Wolfinger is a member of the
Board of Sanguin International Ltd., Burton upon Trent, UK, and was a member of the Supervisory Board of CyBio AG,
Jena, until its Annual General Meeting on June 16, 2009.
The Supervisory Board comprised the following individuals in the year under report:
• Fred K. Brückner, Marburg (Chairman)
Chemical Engineer, Independent Management Consultant
• Dr. Robert Siegle, Birkenfeld (Deputy Chairman)
Lawyer, “Kanzlei Dr. Wille, Dr. Siegle, Zinder GbR“, Pforzheim
• Prof. Dr. Hugo Hämmerle, Weil der Stadt
Graduate in Biology and Director of the Natural and Medical
Science Institute (NMI) at the University of Tübingen, Reutlingen
Member of Supervisory Board from May 20, 2009
• Burkhard G. Wollny, Göppingen
Banker, Landesbank Baden-Württemberg, Stuttgart
Member of Supervisory Board until May 20, 2009
Fred K. Brückner and Dr. Robert Siegle do not hold positions on any other supervisory boards or supervisory bodies as
defined in § 125 (1) Sentence 3 of the German Stock Corporation Act (AktG). Prof. Dr. Hugo Hämmerle is a member of
the Supervisory Boards of TETEC AG, Reutlingen, and Retina Implant AG, Reutlingen. Burkhard G. Wollny is a member of
the Supervisory Board of JBC Jatropha Biofuel Company AG, Stuttgart.
The total compensation of the Supervisory Board amounted to u 119 thousand in the year under report (previous year:
u 108 thousand). The specific structure of the compensation was as follows:
in v thousand 2009 2008
Fixed compensation 36 36
Performance-related components 74 63
Meeting allowance 9 9
Total short-term compensation 119 108
In addition to this total compensation, each member of the Supervisory Board also has his expenses reimbursed and
benefits from a pecuniary damage liability insurance policy concluded at the company’s expense at suitable terms
customary to the market. One member of the Supervisory Board has rights of use for a company vehicle.
“Dr. Wille, Dr. Siegle, Zinder GbR”, Pforzheim, the law firm of Dr. Robert Siegle, a member of the Supervisory Board,
provided STRATEC AG with legal advisory services amounting to around u 34 thousand in the 2009 financial year (previous
year: u 34 thousand). These services were invoiced at prices which would also be agreed with third parties.
Apart from this, there were no service relationships between the company’s directors and officers, or persons closely
related to such, and the companies included in the consolidated financial statements of STRATEC AG.
stratec Annual Report 2009
107